Health Reference LibraryWhich form of inositol should you buy: myo-inositol or D-chiro-inositol?
This entry is part of the Nutri Tailor Health Reference Library — cited research on supplements, nutrients and adjacent areas of health.
Summary
Inositol supplements come in two forms, myo-inositol and D-chiro-inositol, sold alone or blended, most often at a 40:1 myo to D-chiro ratio. Myo-inositol is the sensible default because it carries most of the trial evidence, at research doses of 2 to 4g per day usually split into two doses. The honest caveat sits in the 2023 International PCOS Guideline, which found inositol offers limited clinical benefit in PCOS and that metformin has greater efficacy, so anyone with diagnosed PCOS should discuss the full range of options with their GP. Side effects are uncommon below 12g per day and mainly digestive above it.
How it works
Inositol is a naturally occurring sugar alcohol involved in cellular signalling, including the pathways cells use downstream of insulin, which is why the research literature classes it as an insulin-sensitising agent (Carlomagno 2011). Myo-inositol is the dominant form in the body, and tissues convert a small proportion of it into D-chiro-inositol locally as needed, which is why the two forms are not interchangeable and why blended products copy the plasma proportion rather than a 50:50 split.
Effective dose
The most commonly studied intake of myo-inositol is 2 to 4g per day, usually split into a morning and an evening dose. Mood research has used higher intakes, and the safety review found the maximum tolerated dose in trials was 18g per day (Carlomagno 2011), far above anything needed for the uses most buyers have in mind. There is no UK reference intake for inositol because the body makes its own and obtains more from food.
Forms compared
Myo-inositol is the form most single-ingredient supplements contain and the form carrying most of the randomised trial evidence. D-chiro-inositol is sold alone or blended with myo-inositol, most commonly at a 40:1 myo to D-chiro ratio that mirrors the proportion measured in blood plasma. The systematic review behind the 2023 international guideline pooled 30 randomised controlled trials across inositol in all its forms and judged the evidence inadequate to rank one form above another on clinical outcomes (Fitz 2024), which makes myo-inositol, the form with the largest share of that trial base, the defensible default purchase.
Timing
With or without food, and clock time does not matter. Splitting the daily amount into two doses is the pattern most trials used and is gentler on digestion at higher intakes. Consistency across weeks matters more than timing within the day.
Safety profile
The safety review across clinical trials found digestive effects, mainly nausea, wind and loose stools, appeared only at the highest studied intake of 12g per day, and their severity did not increase with dose (Carlomagno 2011). Intakes of 2 to 4g per day were well tolerated. No UK or EU upper intake level is set.
Special populations
Anyone with diagnosed PCOS should talk to their GP about the full range of options first, because the 2023 international guideline concluded metformin has greater efficacy than inositol for metabolic features (Teede 2023). Anyone using glucose-lowering therapy should also involve their GP or pharmacist before adding an insulin-sensitising supplement. In pregnancy, discuss any supplement with your midwife or GP.
Interactions
Inositol is classed as an insulin-sensitising agent, so the practical caution is glucose-lowering therapy: involve your GP or pharmacist before combining them. No food or mineral separation rules apply, unlike the iron and zinc families.
Guideline positions
2023 International Evidence-based PCOS Guideline (Teede 2023): metformin is recommended primarily for metabolic features and has greater efficacy than inositol, which offers limited clinical benefit in PCOS. Fitz 2024, the systematic review and meta-analysis behind that recommendation: 30 randomised trials, evidence inadequate for evidence-based efficacy recommendations, with limited and inconsistent metabolic and hormonal signals at low to very low certainty. Carlomagno 2011: digestive side effects only at 12g per day and above.
Practical framework
Decide in three steps. First, be clear what the evidence supports: measurable metabolic and hormonal signals exist but are inconsistent, and the international guideline is candid that clinical benefit in PCOS is limited, so buy with honest expectations. Second, choose myo-inositol unless a practitioner has specifically advised a 40:1 blend; it carries most of the trial base and the doses are simple, 2 to 4g per day in two doses. Third, if you want a clean single-ingredient option, myo-inositol in 500mg capsules with no fillers is the worked example on our shelf at nutritailor.co.uk/products/inositol. Diagnosed PCOS goes to your GP for the full picture first.
Common misconceptions
That D-chiro-inositol is the stronger form: the pooled trial evidence cannot rank the forms, and the body makes D-chiro-inositol from myo-inositol locally as needed. That more is better: benefits in trials came at 2 to 4g per day, and digestive effects appear from 12g. That inositol is an established therapy for PCOS: the 2023 international guideline is explicit that clinical benefit is limited and metformin has greater efficacy, which is exactly why realistic expectations and GP input come first.
Forms compared
| Form | What It Is | Evidence Position | Typical Study Dose |
|---|---|---|---|
| Myo-inositol | The dominant form in the body and in the trial literature | Carries nearly all the human evidence; 2023 international guideline judges clinical benefit limited and certainty low | 2 to 4g daily, commonly 2g twice a day |
| D-chiro-inositol | Minor isomer, converted from myo in tissue | Far smaller evidence base; mostly studied inside blends rather than alone | Tens of milligrams within blends |
| 40:1 blend | Myo plus d-chiro at the plasma ratio | Marketed on the physiological ratio; comparative evidence against plain myo remains thin | Ratio products vary; myo component does the work |
Sources
- Teede HJ, Tay CT, Laven JJE, et al; International PCOS Network 2023. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. European Journal of Endocrinology 189(2):G43-G64, DOI 10.1093/ejendo/lvad096, PMID 37580861.
- Fitz V, Graca S, Mahalingaiah S, et al 2024. Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. Journal of Clinical Endocrinology and Metabolism 109(6):1630, PMID 38163998.
- Carlomagno G, Unfer V 2011. Inositol safety: clinical evidences. European Review for Medical and Pharmacological Sciences 15(8):931-936, PMID 21845803.